Peer-influenced content. Sources you trust. No registration required. This is HCN.

The New England Journal of MedicineTeclistamab in Relapsed or Refractory Multiple Myeloma

In this phase 1-2 study, patients with triple-class-exposed relapsed or refractory multiple myeloma experienced a high proportion of profound and long-lasting responses to teclistamab. Infections and cytopenias were frequent, and most grade 1 or 2 toxicities were consistent with T-cell misdirection.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form